Howell Anthony, Wardley Andrew M
CRUK Department of Medical Oncology, University of Manchester, Christie Hospital, 550 Wilmslow Road, Manchester M20 4BX, UK.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S9-S16. doi: 10.1677/erc.1.01003.
Survival in women with breast cancer is improving in the western world, in part related to improved surgery, radiotherapy and adjuvant systemic therapy. Aromatase inhibitors are superior to tamoxifen in this clinical situation and several studies indicate that taxane-based chemotherapy is superior to non-taxane-based regimens. Herceptin is active alone in HER-2/neu +ve advanced breast cancer and four clinical trials are testing this agent in the adjuvant situation. It seems likely that herceptin will add to conventional therapies and thus will be the paradigm for the introduction of other biological therapies to improve cure rates.
在西方世界，乳腺癌女性患者的生存率正在提高，部分原因是手术、放疗及辅助全身治疗有所改善。在这种临床情况下，芳香化酶抑制剂优于他莫昔芬，多项研究表明，紫杉烷类化疗优于非紫杉烷类方案。赫赛汀单药对HER-2/neu阳性晚期乳腺癌有效，四项临床试验正在辅助治疗中对该药物进行测试。赫赛汀似乎有望加入传统疗法，因此将成为引入其他生物疗法以提高治愈率的范例。
